Vulvar & Vaginal Cancer

Yes. Both vulvar and vaginal cancer can occur simultaneously (synchronously) or one after the other (metachronously) in the same woman — a phenomenon driven by HPV-associated lower genital tract field carcinogenesis. Persistent high-risk HPV infection can cause intraepithelial neoplasia and invasive carcinoma at multiple lower genital tract sites (vulva, vagina, cervix) at the same time or at different points in time. Women diagnosed with cancer at one site should always have a thorough examination of all other lower genital tract sites, and women with a prior lower genital tract cancer require lifelong surveillance of all sites.

By FIGO (International Federation of Gynecology and Obstetrics) convention, when a tumor involves both the vulva and the vagina, the entire case is classified and staged as vulvar cancer — not vaginal cancer. Vaginal cancer staging applies only to tumors confined primarily to the vaginal canal. This distinction matters because vulvar and vaginal cancers have different FIGO staging systems, different lymph node drainage pathways, and different radiation field designs. The treating gynecologic oncology team will clarify which staging and treatment framework applies to your specific case.

HPV field carcinogenesis refers to the process by which persistent high-risk HPV infection causes widespread DNA damage across the entire HPV-exposed lower genital tract — including the cervix, vagina, and vulva — rather than at a single focal point. This means that a woman who develops cancer or high-grade precancerous change at one site is at elevated risk of having similar changes at other sites. It also explains why treatment of one site does not eliminate the risk at the others, and why lifelong surveillance of the entire lower genital tract is necessary after any HPV-associated lower genital tract diagnosis.

Treatment depends on the stage, histologic subtype, and anatomic extent of disease at each site. For early combined disease, surgery may resect both sites in the same operative setting, with sentinel node biopsy or lymph node dissection for the vulvar component. For locally advanced combined disease — particularly when resection would cause unacceptable functional loss to the bladder, rectum, or urethra — concurrent cisplatin-based chemoradiation is the preferred primary treatment. Brachytherapy is used to boost the vaginal component of disease. Adjuvant immunotherapy (pembrolizumab) and clinical trials are options for high-risk or recurrent disease. All combined disease cases should be discussed at a gynecologic oncology multidisciplinary team meeting before treatment begins.

Brachytherapy is a radiation technique in which radioactive sources are placed directly inside or immediately adjacent to the vaginal tumor, delivering a high dose of radiation to the target while minimizing exposure to surrounding structures. For vaginal cancer, intracavitary brachytherapy (using a vaginal cylinder or ring applicator) is used for early, superficial lesions. Interstitial brachytherapy — using implanted needles — is used for more bulky or deeply invasive vaginal tumors. Brachytherapy is typically combined with external beam radiation for comprehensive treatment. It requires specialist gynecologic radiation oncology expertise and specialized equipment available at specialist cancer centers.

Diethylstilbestrol (DES) is a synthetic estrogen that was prescribed to pregnant women from the 1940s through the 1970s to prevent miscarriage. Women who were exposed to DES in utero (before birth) have an elevated risk of developing clear cell adenocarcinoma of the vagina — a rare but serious cancer that typically presents in adolescence or early adulthood. DES-exposed women also commonly develop vaginal adenosis (glandular tissue in the vaginal wall) and structural vaginal abnormalities. Regular gynecologic surveillance is recommended for all known DES-exposed women.

Yes. Pembrolizumab (anti-PD-1 checkpoint inhibitor) has demonstrated activity in recurrent or metastatic squamous cell carcinoma of both the vulva and vagina, particularly in tumors with PD-L1 expression (CPS ≥1 or ≥10). It is used as second-line or later therapy for patients who have progressed on platinum-based chemotherapy. Clinical trials are also evaluating pembrolizumab in combination with chemoradiation for locally advanced disease. PD-L1 testing and comprehensive molecular profiling are recommended for all patients with recurrent or metastatic lower genital tract SCC.

Long-term effects from treatment of combined lower genital tract cancer include: vaginal stenosis and reduced sexual function from radiation and surgery; lower limb lymphedema from inguinal or pelvic lymph node dissection and radiation; urinary symptoms (frequency, urgency, or incontinence) from radiation to the bladder; bowel symptoms from rectal radiation effects; and psychological impacts on body image, femininity, and intimate relationships. Comprehensive supportive care including pelvic floor physiotherapy, vaginal dilator use, sexual health counseling, and lymphedema management substantially improves quality of life after treatment.

Surveillance should continue for a minimum of 5 years with clinical examination every 3 months for the first 2 years, then 6-monthly to 5 years. Given the field carcinogenesis risk — particularly in HPV-associated disease — lifelong gynecologic surveillance of all lower genital tract sites is generally recommended, even after the 5-year mark. Annual cervical screening (if the cervix is intact), vaginal vault smears (if the cervix has been removed), and colposcopic examination of the vulva and vaginal walls are the main surveillance components. Any new symptom should prompt immediate evaluation regardless of the interval since last review.

Yes. CancerFax supports patients with combined vulvar and vaginal cancer throughout their treatment journey. Our services include specialist gynecologic oncology report review, second opinions on staging and combined-site surgical planning, radiation field design consultation, immunotherapy and clinical trial eligibility assessment, and coordination with specialist centers — including high-volume gynecologic oncology centers and brachytherapy-capable centers in China and globally. For patients with rare histologies (melanoma, clear cell, sarcoma) at either site, CancerFax provides access to subtype-appropriate specialist expertise. Share your medical reports with our team to begin.